Pfizer Inc. (PFE) AD Drug Meets Phase 2 Primary Endpoint

Pfizer reported Phase 2 results for tilrekimig in atopic dermatitis, with a 61% EASI-75 response rate at a monthly 200 mg dose, compared to 9.1% on placebo. The study is ongoing, with Phase 3 trials initiated. Pfizer shares closed at $28.52 on Sept. 30, before the detailed data release.

Pfizer's Phase 2 study of tilrekimig (PF-07275315) in moderate-to-severe atopic dermatitis met its primary endpoint, showing significant skin clearance at Week 16. The study reported EASI-75 rates of 62.5% for 450 mg Q2W and 58.5%-61.0% for 200-400 mg Q4W doses, compared to 19.9%-9.1% for placebo. Tilrekimig was well-tolerated, with no dose-dependent safety signals. Pfizer has initiated Phase 3 trials for tilrekimig in atopic dermatitis, asthma, and COPD.

Pfizer (PFE) acquired Metsera, gaining PF-3944, a GLP-1 obesity drug showing 12.3% weight loss in trials. The company aims for 2028 regulatory approval in the weight-loss market. Additionally, Pfizer reported positive data for tilrekimig in dermatology trials, showing significant improvements over placebo.

Pfizer (NYSE:PFE) reported positive Phase 2 results for tilrekimig, an atopic dermatitis drug. The study met its primary endpoint, with 62.5% of patients achieving EASI-75 in Stage 1. The drug is designed to inhibit specific interleukins and has an extended half-life. Phase 3 trials are underway for atopic dermatitis and asthma. Adverse events were reported in 46.7% of patients in the 450 mg group in Stage 1.

Pfizer, BioNTech, and Moderna lost a bid to dismiss lawsuits from Bayer's Monsanto unit over mRNA technology patents. The judge denied their requests to dismiss the case.

A federal judge declined to dismiss Bayer's patent lawsuits against Pfizer, BioNTech, and Moderna over mRNA technology used in their COVID-19 vaccines. Bayer claims the companies infringed on Monsanto's 1980s patent for stabilizing mRNA in crops. The vaccine makers argue their processes differ and that the patent covers a 'law of nature'.